BROMOPRIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H22BrN3O2
Molecular Weight	344.247
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC

InChI

InChIKey=GIYAQDDTCWHPPL-UHFFFAOYSA-N

InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)

HIDE SMILES / InChI

Molecular Formula	C14H22BrN3O2
Molecular Weight	344.247
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14871277 | http://www.medicinanet.com.br/bula/1015/bromopan.htm

Bromopride is a dopamine D2 receptor blocker. Bromopride exerts is a gastrointestinal prokinetic exploited clinically for the management of motor disorders of the upper gastrointestinal tract, including functional dyspepsia, gastric stasis of various origins and emesis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 311 Target ID: CHEMBL339 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14871277 \| https://www.ncbi.nlm.nih.gov/pubmed/7823770	Antagonist 2849
cholinesterase activity 5 Target ID: GO:0004104 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7823770	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dyspepsia 11 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28778685	Primary		Approved 8583	Bromopan Approved Use Principais: distúrbios digestivos psicossomáticos ad senectude e da estafa mental. Discinesias gastroduodenais e biliares. Colopatias espasmódicas. Enxaquecas e mal-estar de origem celíaca. Náuseas. Vômitos. Anorexia. Particulares: exames radiológicos do tubo digestivo. Preparação de explorações endoscópicas. Vômitos anestésicos. Soluços. Meteorismo abdominal pós-operatório. Manifestações digestivas após a aplicação de radioterapia.

C_max

Value	Dose	Analyte	Population
58 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3730521/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BROMOPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
25 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3730521/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMOPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
127 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3730521/	20 mg single, intramuscular dose: 20 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	BROMOPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
194 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3730521/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BROMOPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
191 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3730521/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMOPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
680 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3730521/	20 mg single, intramuscular dose: 20 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	BROMOPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
2.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3730521/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BROMOPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3730521/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMOPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3730521/	20 mg single, intramuscular dose: 20 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	BROMOPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
60% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3730521/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BROMOPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
60% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3730521/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMOPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
60% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3730521/	20 mg single, intramuscular dose: 20 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	BROMOPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
30 mg single, oral Highest studied dose Dose: 30 mg Route: oral Route: single Dose: 30 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3730521/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3730521/	Sources: https://pubmed.ncbi.nlm.nih.gov/3730521/
0.15 mg/kg single, intramuscular Studied dose Dose: 0.15 mg/kg Route: intramuscular Route: single Dose: 0.15 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/28778685/	unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/28778685/	Other AEs: Somnolence, Somnolence... Other AEs: Somnolence (44.1%) Somnolence (16.9%) Diarrhea (5.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/28778685/

AEs

AE	Significance	Dose	Population
Somnolence	16.9%	0.15 mg/kg single, intramuscular Studied dose Dose: 0.15 mg/kg Route: intramuscular Route: single Dose: 0.15 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/28778685/	unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/28778685/
Somnolence	44.1%	0.15 mg/kg single, intramuscular Studied dose Dose: 0.15 mg/kg Route: intramuscular Route: single Dose: 0.15 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/28778685/	unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/28778685/
Diarrhea	5.1%	0.15 mg/kg single, intramuscular Studied dose Dose: 0.15 mg/kg Route: intramuscular Route: single Dose: 0.15 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/28778685/	unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/28778685/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
BSEP 550 MRP4 290 MRP3 246 CYP2C19 2057 CYP1A2 2153 MRP2 499 OATP1B1 1079 OATP1B3 961 CYP19A1 429 P-gp 1741	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDM5OTUxMCJ9fQ==	inconclusive [IC50 10 uM]
CYP2D6 2546	inhibitor 4027 Sources: eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMzk5NTEwIn19	inconclusive [IC50 5.0119 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDM5OTUxMCJ9fQ==	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDM5OTUxMCJ9fQ==	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMzk5NTEwIn19	no [IC50 >10 uM]
BSEP 554	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDM5OTUxMCJ9fQ==	no [IC50 >133 uM]
MRP2 625	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1NzQ4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDM5OTUxMCJ9fQ==	no [IC50 >133 uM]
MRP3 326	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1OTE4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDM5OTUxMCJ9fQ==	no [IC50 >133 uM]
MRP4 345	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDM5OTUxMCJ9fQ==	no [IC50 >133 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/2446#section=BioAssay-Results Page: 228.0	no
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/2446#section=BioAssay-Results Page: 10.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDM5OTUxMCJ9fQ==	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDM5OTUxMCJ9fQ==	yes [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/2446#section=BioAssay-Results Page: 255 \| 267	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/2446#section=BioAssay-Results Page: 6.0

PubMed

Title	Date	PubMed
Case-crossover study of Burkholderia cepacia complex bloodstream infection associated with contaminated intravenous bromopride.	2010-05	20205589
Influence of bromopride in the prophylaxis of nausea associated with fluorescein angiography.	2006-01-17	17505728
Validated method for determination of bromopride in human plasma by liquid chromatography--electrospray tandem mass spectrometry: application to the bioequivalence study.	2005-09	16127659
Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass.	2005-05	15946465

Patents

Sample Use Guides

In Vivo Use Guide

Capsules: 40-60 mg/day Oral solution: 40-60 mg/day (adults), 0.5-1 mg/kg (children)

Route of Administration: Oral

In Vitro Use Guide

Bromopride effects on cholinesterase activity in plasma, striatum, duodenum and ileum of adult male rats were measured for drug concentrations ranging from 0.006 to 3.134 microM. Bromopride can inhibit cholinesterase activity in all tissues studied,

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:17:08 GMT 2025` Edited by `admin` on `Mon Mar 31 18:17:08 GMT 2025`
Record UNII	75473V2YZK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MOVIPRIDE

Preferred Name

English

BROMOPRIDE

Official Name

English

BROMOPRIDE [MI]

Common Name

English

bromopride [INN]

Common Name

English

NSC-758391

Code

English

BROMOPRIDE [MART.]

Common Name

English

4-AMINO-5-BROMO-N-(2-(DIETHYLAMINO)ETHYL)-O-ANISAMIDE

Common Name

English

Bromopride [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

A03FA04